Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. x x. 46/2008 Xx. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 1. xxxxx 2017 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu pro xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx¹⁾.

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx a xxxxxxxxx republiky xxxxxxxx xxxxxxx x přijetí xxxx Přílohy I Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Úmluvy xxx 1. ledna 2018. Pro Českou xxxxxxxxx xxxxxxxxx xxxx xxxxx Xxxxxxx I x platnost dne 5. června 2019.

Xxxx xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I xxxxxx od 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Anglické xxxxx xxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH LÁTEK X XXXXX XXXXXXX XXX XXX 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx spravován XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx mezi xxxxxxxxx x francouzskou verzí xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx od 1. xxxxx 2018 

SEZNAM ZAKÁZANÝCH XXXXX A METOD XXXXXXX PRO ROK 2018

XXXXXXX ANTIDOPINGOVÝ KODEX

Platný xx 1. ledna 2018

XXXXX A METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx za "Specifické xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, syntetické drogy, xxxxx schválené xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX):

(x) Xxxxxxxx* AAS, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion);

1-androsteron (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-dihydroxyandrost-4-en-3-on);

kalusteron;

klostebol;

mestanolon;

mesterolon;

metandienon (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-hydroxy-5α-androst-1-en-3-on);

tetrahydrogestrinon (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

b. Xxxxxxxxx** XXX, xxxxx jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx a xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM, xxxx. xxxxxxx, XXX-4033, xxxxxxx x RAD140); tibolon; xxxxxxx a xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx na xx.

Xxx účely xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx přirozeně neprodukuje. ** "xxxxxxxxx " xx xxxxxxxx k látce, xxxxxx xxxx normálně xxxxxxxxx produkuje.

S2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ FAKTORY, XXXXXXXX LÁTKY A XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx s xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx receptoru, např

darbepoetiny (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx XXX (XXX-Xx, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx (xxxx. CNTO 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, např.

K-11706.

1.4 Xxxxxxxxxx TGF - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx xxxxxxxxx opravného xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx EPO.

2. Peptidové xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx hormon (XX) a xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin, x xxxx.

2.2 Kortikotropiny a xxxxxx uvolňující xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxxxx a uvolňující xxxxxxx, včetně, xxx xx x omezením xxxxx na xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho xxxxxxx, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx hormonu (GHS), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxxx; uvolňující peptidy xxxxxxxxx hormonu (XXXX), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5, GHRP-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx faktorů, xxxxxx, xxx xx s xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx růstové faktory (XXXx);

xxxxxxxxxxxx xxxxxxx faktor (XXX);

xxxxxxxx xxxxxxx růstový xxxxxx-1 (IGF-1) a xxxx analoga

mechanické xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF).

Další xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. BETA2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x neselektivní xxxx-2 agonisté, xxxxxx xxxxx xxxxxxxxx isomerů, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx s omezením xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; vilanterol.

Výjimkou xxxx:

• xxxxxxxxx xxxxxxxxxx: maximálně 1600 xxxxxxxxxx xx 24 xxxxx v xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx xx xxxxxxxxx dávce;
• inhalační xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 hodin;
• inhalační salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 ng/ml nebude xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx považována za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální výsledek xxx způsoben xxxxxxxxxxxxx xxxxxx (x inhalaci) xxxxx, xxx výše xxxxxxx maximální dávka.

S4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x metabolické xxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx xx x xxxxxxxx pouze xx xx.

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 meldonium;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx diuretika a xxxxxxxxx látky xxxx xxxxxxxx, xxxxxx xxxx xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (xxxx. xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); xxxxxxxxxx, xxx xx x omezením xxxxx na ně.

• Acetazolamid; xxxxxxxx; bumetanid; furosemid; xxxxxxxxxxxx; indapamid; xxxxxxxx; xxxxxxxx xxxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid); xxxxxxxxxx x vaptany (xxxx. xxxxxxxxx), ale xx s xxxxxxxx xxxxx xx ně.

S xxxxxxxx:

• xxxxxxxxxxxx; pamabromu a xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx pro zubní xxxxxxxxx

Xxxxx jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Při Soutěži xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález, pokud Xxxxxxxxx xxxx schválenou Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx k xx, xxxxx již byla xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X KRVÍ X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv množství xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní krve xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv původu xx oběhového xxxxxxx.

2. Xxxxx zvyšování xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx hemoglobinové produkty (xxxx. xxxxxx náhražky xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx kyslíkem zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx. To xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx ne x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx xxxxxx x/xxxx injekce více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX DOPING

Z xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx následující:

1. Xxxxxxx xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx sekvencí genomu x/xxxx x xxxxxxxxxxxx xxxx epigenetické xxxxxxxx xxxxxx exprese.

3. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 a X1 xx X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:

ZAKÁZANÉ XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx stimulancia:

Adrafinil;

amfepramon;

amfetamin;

amfetaminil;

amifenazol;

benfluorex;

benzylpiperazin;

bromantan;

fendimetrazin;

fenetylin;

fenfluramin;

fenkamin;

fenproporex;

fentermin;

fonturacetam /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, které xxxx výslovně uvedeno x xxxxx xxxxxxxx, xx Specifickou xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx na ně):

Adrenalin (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx a jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon a xxxx xxxxxxx (např. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (metylsynefrin);

pemolin;

pentetrazol;

propylhexedrin;

pseudoefedrin*****;

selegilin;

sibutramin;

strychnin;

tenamfetamin (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx místního/očního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2018*.

* Xxxxxxxxx, fenylefrin, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Tyto xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2018 x xxxxxx xxxxxxxxxx za Xxxxxxxx xxxxx.

** Xxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx než 5 mikrogramů x 1 xx moči.

*** Xxxxxxx a xxxxxxxxxxxxx: xxxx zakázány xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): není xxxxxxx při lokálním xxxxxx, např. xxxxx, xxxx xxxxxxxx xxxx xxxx podání xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: je xxxxxxx, xxxxx jeho koncentrace x moči xx xxxxx xxx 150 xxxxxxxxxx na mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx kanabinoidy xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. xxxxx, konopí x marihuana.

• Syntetické kanabinoidy, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.

Xxxxxx, xxx xx s xxxxxxxx pouze xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, a kde xx to xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx na lyžích x akrobatické xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx U-rampa a "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx potápění) (CMAS) x disciplínách xxxxxxxxxx xxxx x ploutvemi xxxx xxx xxxxxxx, xxxxxxxxx apnoe x xxxxxxxxx xxxx bez xxxxxxx, free immersion, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx terč x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx ne s xxxxxxxx pouze xx xx.

Informace

Právní xxxxxxx č. 36/2019 Xx. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Sb. x. x. xxx xxxxxx xxxxxxx předpisem č. 32/2023 Sb. m. s. x účinností xx 22.8.2023.

Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se jich xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx dopingu ve xxxxxx, xxxxxxx dne 19. xxxxx 2005 x Paříži, byla xxxxxxxxx x xxxxxxxxx xxxxx x x xxxxxxxxx xx xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Úmluvy xx českého xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.